Skip to main content
About
Contact
Subscribe
e-Edition
Make Home Page
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Twitter
Toggle navigation
Site search
Search
Home
Contact Us
Advertise
Subscription Services
Promote Your Event
Submission Forms
News
Local News
National
World
Archives
Sports
Local Sports
National Sports
Business
Local Business
National Business
Technology
Markets & Stocks
Opinion
Columns
Editorials
Letters To The Editor
Polls
Thumbs
A & E
Local Entertainment
Art Scene
Music Scene
Theatre Scene
Book Reviews
Movie Reviews
TV Listings
Local Events
What To Do
Life
Health
Travel
Oddities
Community Directory
Community Service
Rescue Me
Other
Magazines
Fall Home Improvements 2024
Women
Home & Realty
Outdoor Guide
Premier Home Style Tour 2024
Spring Home & Garden Show 2024
Spring on the Road
Spring Wellness 2025
Classifieds
Place Ad
Careers
Tenders
Weather
Obituaries
Parcel Pickup
Ontario Votes
Auction 2025
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Syros Pharmaceuticals, Inc. - Common Stock
(NQ:
SYRS
)
0.1172
UNCHANGED
Last Price
Updated: 4:00 PM EDT, Mar 19, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Syros Pharmaceuticals, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
10
11
Next >
Syros Provides Update on SELECT-AML-1 Phase 2 Clinical Trial
August 12, 2024
From
Syros Pharmaceuticals
Via
Business Wire
Syros Reports Second Quarter 2024 Financial Results and Provides a Business Update
July 31, 2024
From
Syros Pharmaceuticals
Via
Business Wire
Syros to Report Second Quarter 2024 Financial Results on Wednesday, July 31, 2024
July 24, 2024
From
Syros Pharmaceuticals
Via
Business Wire
Syros Pharmaceuticals's Earnings Outlook
March 26, 2024
Via
Benzinga
Syros to Host Webcast Event on Higher-Risk Myelodysplastic Syndrome and the Opportunity for Tamibarotene to Become the New Frontline Standard-of-Care for Patients with RARA Gene Overexpression
June 13, 2024
From
Syros Pharmaceuticals
Via
Business Wire
SYRS Stock Earnings: Syros Pharmaceuticals Beats EPS for Q1 2024
May 14, 2024
SYRS stock results show that Syros Pharmaceuticals beat analyst estimates for earnings per share the first quarter of 2024.
Via
InvestorPlace
Syros Reports First Quarter 2024 Financial Results and Provides a Corporate Update
May 14, 2024
From
Syros Pharmaceuticals
Via
Business Wire
Syros to Participate in Upcoming Investor Conferences
May 07, 2024
From
Syros Pharmaceuticals
Via
Business Wire
Syros to Report First Quarter 2024 Financial Results on Tuesday, May 14, 2024
May 07, 2024
From
Syros Pharmaceuticals
Via
Business Wire
Crude Oil Down Over 1%; Cognyte Software Shares Plummet
April 09, 2024
U.S. stocks traded lower toward the end of trading, with the S&P 500 falling around 0.4% on Tuesday. The Dow traded down 0.46% to 38,713.72 while the NASDAQ fell 0.24% to 16,215.32. The S&P 500 also...
Via
Benzinga
Topics
Stocks
Exposures
Fossil Fuels
US Equities
12 Health Care Stocks Moving In Tuesday's Intraday Session
April 09, 2024
Via
Benzinga
Syros Receives Fast Track Designation from the FDA for Tamibarotene for the Treatment of Newly Diagnosed Unfit AML with RARA gene overexpression
April 09, 2024
From
Syros Pharmaceuticals
Via
Business Wire
Why Tilray Brands Shares Are Trading Lower By Around 22%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
April 09, 2024
Shares of Tilray Brands, Inc. (NASDAQ: TLRY) fell sharply during Tuesday’s session after the company missed third-quarter estimates and said it no longer expects to generate positive adjusted free
Via
Benzinga
Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
April 02, 2024
From
Syros Pharmaceuticals
Via
Business Wire
Top 3 Health Care Stocks You'll Regret Missing This Month
April 02, 2024
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
Via
Benzinga
SYRS Stock Earnings: Syros Pharmaceuticals Misses EPS, Misses Revenue for Q4 2023
March 27, 2024
SYRS stock results show that Syros Pharmaceuticals missed analyst estimates for earnings per share and missed on revenue for the fourth quarter of 2023.
Via
InvestorPlace
Syros Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Corporate Update
March 27, 2024
From
Syros Pharmaceuticals
Via
Business Wire
Syros Announces Completion of Enrollment of 190 Patients Necessary to Support Primary Endpoint Analysis in SELECT-MDS-1 Phase 3 Trial
March 25, 2024
From
Syros Pharmaceuticals
Via
Business Wire
Earnings Scheduled For March 27, 2024
March 27, 2024
Companies Reporting Before The Bell • Local Bounti (NYSE:LOCL) is projected to report quarterly loss at $2.41 per share on revenue of $8.70 million.
Via
Benzinga
Syros to Report Fourth Quarter and Full Year 2023 Financial Results on Wednesday, March 27, 2024
March 20, 2024
From
Syros Pharmaceuticals
Via
Business Wire
A Look Into Healthcare Sector Value Stocks
March 11, 2024
Via
Benzinga
Syros to Participate in TD Cowen 44th Annual Health Care Conference
February 27, 2024
From
Syros Pharmaceuticals
Via
Business Wire
Overview Of Value Stocks In The Healthcare Sector
February 12, 2024
Via
Benzinga
3 Once-in-a-Lifetime Penny Stocks With Unprecedented Surge Potential
January 31, 2024
Is your portfolio is in dire need of making new all-time highs? A new economic cycle is to send these penny stocks with potential up.
Via
InvestorPlace
5 Value Stocks To Watch In The Healthcare Sector
January 29, 2024
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
January 09, 2024
Via
Benzinga
Syros Highlights Anticipated 2024 Milestones to Deliver on the Value of Tamibarotene
January 08, 2024
From
Syros Pharmaceuticals
Via
Business Wire
5 Value Stocks To Watch In The Healthcare Sector
January 01, 2024
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
December 19, 2023
Via
Benzinga
Syros Announces Pricing of $45.0 million Underwritten Offering of Common Stock and Pre-Funded Warrants
December 19, 2023
From
Syros Pharmaceuticals
Via
Business Wire
< Previous
1
2
3
4
5
6
7
8
9
10
11
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.